Date: July 2, 2021

DISCIPLINE: GENOMICS

Tumour Testing for *BRCA1/BRCA2*

Date effective: July 2, 2021

Background Information:

Tumour-based testing is available for patients diagnosed with high-grade serous adenocarcinoma of ovarian, fallopian tube, or peritoneal origin. This service is now offered in-house through the Molecular Diagnostics Laboratory, Genomics, Diagnostic Services.

This test can be ordered by Shared Health pathologists and CancerCare Manitoba gynecologic oncologists.

Preferred specimen type is FFPE tissue block with a minimum of 20% tumour content, or cytology specimens (cell blocks) with a minimum of 10% tumour cellularity. Alternatively, if no adequate tissue is available, a peripheral blood specimen can be used to determine a patient's germline *BRCA1/BRCA2* status.

Refer to the current versions of requisitions and laboratory policies for specimen requirements.

Change in Test Procedure:

- Prior to June 28, 2021, this test was sent to University Health Network (UHN) Genome Diagnostics Lab.

References/Resources:

- R250-10-61 KR001 Molecular Pathology Requisition – use for test requests on FFPE tissue
- R250-10-10 Molecular Diagnostic Laboratory - Hereditary Cancer Test Requisition – use for test requests on peripheral blood
- Shared Health Pathologists only – Refer to 170-10-66 *BRCA Testing*

Patient Impact:

- This test will serve to identify actionable variants in *BRCA1* and *BRCA2* genes. Patients with an actionable *BRCA1* and *BRCA2* variant may benefit from PARP inhibitor therapy.

System Improvements:

- By performing the test in-house, a shorter turn-around-time for results is expected.

For More Information Contact:

- Dr. Elizabeth Spriggs, Medical Director, Genomics, Diagnostic Services bspriggs@sharedhealthmb.ca
- Dr. Paul Park, Associate Medical Director, Genomics, Diagnostic Services, Shared Health ppark@sharedhealthmb.ca
- Dr. Ronald Agatep, Molecular Geneticist, Genomics, Diagnostic Services ragatep@sharedhealthmb.ca